299.01
Bio Rad Laboratories Inc stock is traded at $299.01, with a volume of 192.86K.
It is down -0.28% in the last 24 hours and up +0.19% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$298.29
Open:
$296.8
24h Volume:
192.86K
Relative Volume:
0.51
Market Cap:
$7.97B
Revenue:
$2.59B
Net Income/Loss:
$168.80M
P/E Ratio:
49.22
EPS:
6.0748
Net Cash Flow:
$357.20M
1W Performance:
+5.32%
1M Performance:
+0.19%
6M Performance:
-2.11%
1Y Performance:
+22.18%
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BIO
Bio Rad Laboratories Inc
|
297.84 | 7.98B | 2.59B | 168.80M | 357.20M | 6.0748 |
|
ABT
Abbott Laboratories
|
93.41 | 162.41B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
331.47 | 121.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
80.53 | 103.07B | 36.36B | 4.84B | 5.43B | 3.7212 |
|
BSX
Boston Scientific Corp
|
44.31 | 65.70B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
90.48 | 51.66B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 6.5% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad rises as life-science tools deal activity and activist interest appear to lift sentiment - Quiver Quantitative
Bio-Rad Laboratories Jumps 5.6% Amid Sector-Wide Rally - AlphaStreet
BIO Forecast — Price Target — Prediction for 2027 - TradingView
Lyme Disease Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Abbott, Bio-Rad Labs, Covance Inc.F. Hoffmann-La Roche AG, T2 Biosystems - Barchart.com
Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035 at a 8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - AOL.com
Bio Rad Laboratories Inc (BIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
Bio Rad Laboratories Inc (BIO) Institutional Confidence - TradingKey
Why Bio-Rad’s Bio-Plex Pro Human Cytokine Screening Panel still matters in the lab - Ad-hoc-news.de
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIOb) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio Rad Laboratories Inc (BIOb) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio Rad Laboratories Inc (BIOb) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bio Rad Laboratories Inc (BIOb) Institutional Confidence - TradingKey
Bio Rad Laboratories Inc (BIOb) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIOb) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bio Rad Laboratories Inc (BIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bio Rad Laboratories Inc (BIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio Rad Laboratories Inc (BIOb) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIOb) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bio Rad Laboratories Inc (BIOb) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
From Concept To Cure: Using AAV In Gene Therapy - Pharmaceutical Online
(BIO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
In Fight With GC, Bio-Rad Adds Quinn Emanuel to Legal Team - Law.com
Bio-Rad Receives MicroVal Validation for Two EZ-Check Listeria Testing Kits - Quality Assurance & Food Safety
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Limited Upside Amid a Competitive Landscape - DirectorsTalk Interviews
BIO - Finviz
Bio-Rad receives MicroVal validation for EZ-Check™ Listeria testing kits - News-Medical
Elliott builds big stake in life-science firm Bio-Rad Labs, WSJ reports - MSN
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
In Vitro Diagnostic (IVD) Quality Control Market Overview, Key - openPR.com
(BIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
BioRad Listeria Test Kits Receive MicroVal Certification - Food Safety Magazine
Bio-Rad receives microVal validation for EZ-CheckTM Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits - Cambridge Network
Bio-Rad (BIO) Q1 2026 Earnings Transcript - AOL.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Tight Market with Strategic Growth Potential - DirectorsTalk Interviews
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching - 富途牛牛
Bio-Rad Is a Strategic Investor in Sartorius, With Around $5B Stake -- WSJ - Moomoo
A Look at Bio-Rad Laboratories Inc (BIO) After 4.2% Gain -- GF V - GuruFocus
[144] BIO-RAD LABORATORIES, INC. SEC Filing - Stock Titan
Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l - AD HOC NEWS
Bio-Rad’s valuation may be hard to justify as revenue growth lags industry forecasts. Optimistic investor sentiment could reverse if growth fails to improve, potentially putting pressure on the stock. - Moomoo
Is Elliott’s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)? - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Medical Device Terrain with a 3.22% Upside - DirectorsTalk Interviews
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):